Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Anabolic treatment"'
Autor:
Maggie Tabberer, Nicola Williamson, Sophi Tatlock, Adam Gater, Rebecca Grimes, Chika Akinseye, David Neil, Aoife Mahon-Smith, Linda Nelsen
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 8, Iss 1, Pp 1-14 (2024)
Abstract Background Chronic obstructive pulmonary disease (COPD) and muscle weakness can cause impaired physical function, significantly impacting patients’ health-related quality of life (HRQoL). Loss of muscle strength is usually assessed through
Externí odkaz:
https://doaj.org/article/c9b41cbf936b4a06a8b85fdcffd752d7
Autor:
Tatiane Vilaca, Richard Eastell
Publikováno v:
JBMR Plus, Vol 7, Iss 11, Pp n/a-n/a (2023)
Abstract Diabetes is characterized by hyperglycemia, but the two main types, type 1 diabetes (T1D) and type 2 diabetes (T2D), have distinct pathophysiology and epidemiological profiles. Individuals with T1D and T2D have an increased risk of fractures
Externí odkaz:
https://doaj.org/article/fb51f14cc6b14146a73112e76db00cae
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Despite the continued development of specialized immunosuppressive therapies in the form of monoclonal antibodies, glucocorticoids remain a mainstay in the treatment of rheumatological and auto-inflammatory disorders. Therapeutic glucocorticoids are
Externí odkaz:
https://tud.qucosa.de/id/qucosa%3A90490
https://tud.qucosa.de/api/qucosa%3A90490/attachment/ATT-0/
https://tud.qucosa.de/api/qucosa%3A90490/attachment/ATT-0/
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
Despite the continued development of specialized immunosuppressive therapies in the form of monoclonal antibodies, glucocorticoids remain a mainstay in the treatment of rheumatological and auto-inflammatory disorders. Therapeutic glucocorticoids are
Externí odkaz:
https://doaj.org/article/73af846875574098b9572e11da02d9b7
Autor:
Charlotte Beaudart, Stuart Silverman, Deborah T. Gold, Setareh A. Williams, Rich Weiss, Mickael Hiligsmann
Publikováno v:
Archives of Osteoporosis, 17(1):57. Springer-Verlag London Ltd.
Mini abstract US patients with osteoporosis included in three focus groups identified efficacy, safety, cost, and convenience as important attributes of treatment when choosing between anabolic therapies with high stated preference for the solid Micr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c802c3457c0415a237aae583af34297b
https://doi.org/10.1007/s11657-022-01075-z
https://doi.org/10.1007/s11657-022-01075-z
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Clinical Medicine, Vol 10, Iss 1403, p 1403 (2021)
Journal of Clinical Medicine
Journal of Clinical Medicine
Teriparatide has proven effective in reducing both vertebral and non-vertebral fractures in clinical trials of post-menopausal and glucocorticoid-induced osteoporosis. Widespread adoption of Teriparatide over the last two decades means that there is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c164bc6de65e815b6d7488f2b43be8f6
https://www.mdpi.com/2077-0383/10/7/1403
https://www.mdpi.com/2077-0383/10/7/1403
Autor:
Mattias Lorentzon
Publikováno v:
Journal of Internal Medicine. 285:381-394
Antiresorptive drugs, such as the bisphosphonates and the RANKL inhibitor denosumab, are currently the most widely used osteoporosis medications. These drugs increase bone mineral density (BMD) and reduce the risk of vertebral (by 40–70%), nonverte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f8a6011df5f47be9f8c260577c127d2
https://doi.org/10.1111/joim.12873
https://doi.org/10.1111/joim.12873